• Mashup Score: 0

    In the dynamic realm of immuno-oncology, breakthroughs are continually forged, yet challenges endure. The laudable success of immune checkpoint inhibitors such as anti–programmed cell death 1 protein (PD-1)/programmed cell death 1 ligand 1 (PD-L1), while transforming therapeutic landscapes, has yet…

    Tweet Tweets with this article
    • Great editorial by @HajjarJoud @MDerbalaMD @ANaingMD @JAMAOnc https://t.co/rEvZuJ9wa1 The role of “T-cell immunoreceptor with Ig and ITIM domains (TIGIT)” in immune suppression propelled extensive development of TIGIT inhibitors by over 15 pharmaceutical entities.

  • Mashup Score: 1

    Ji Son, Heather Y. Lin, Siqing Fu, Amadeo B. Biter, Ecaterina E. Dumbrava, Daniel D. Karp, Aung Naing, Shubham Pant, Sarina A. Piha-Paul, Jordi Rodon, Vivek Subbiah, Apostolia M. Tsimberidou, Timothy A. Yap, Michael M. Frumovitz, Amir A. Jazaeri, Pedro T. Ramirez, Shannon N. Westin, Ying Yuan, Funda Meric-Bernstam, David S. HongJ Immunother Precis Oncol. 2023 Feb; 6(1): 10–18. Published online…

    Tweet Tweets with this article
    • RT @JIPOEditors: Have you heard? #JIPO is now indexed in PubMed Central! https://t.co/HYDbA7epeC @ANaingMD @weoncologists @SewantiLimaye…